For all the talk about the Trump era leading to cozier relations with Russia, the new U.S. president hasnt completely won over every CEO in Moscow.
Everyone should wait and see what actually happens, and Russias peppier mood is based on more than just Donald Trump moving into the White House.
So says Oliver Hughes, chief executive at Tinkoff Bank, a Russian company that bills itself as the worlds largest stand-alone online bank in terms of number of customers (it has 5 million).
investment software: Fluor Corporation(FLR)
- [By David Zeiler]
Construction stocks Fluor (NYSE: FLR) and Granite Construction Inc. (NYSE: GVA) both rose about 8%; Vulcan Materials Co. (NYSE: VMC) jumped nearly 10%.
- [By Paul Ausick]
Fluor Corp. (NYSE: FLR) dropped about 6.3% Monday to post a new 52-week low of $41.78 after closing at $44.58 on Friday. The stock’s 52-week high is $58.37. Volume of about 3.5 million was more than double the daily average. The company had no specific news.
investment software: J & J Snack Foods Corp.(JJSF)
- [By Monica Gerson]
J & J Snack Foods Corp (NASDAQ: JJSF) is estimated to post its quarterly earnings at $0.78 per share on revenue of $231.58 million.
Nabors Industries Ltd. (NYSE: NBR) is expected to post a quarterly loss at $0.33 per share on revenue of $630.85 million.
investment software: iShares Core S&P 500 (IVV)
- [By WWW.GURUFOCUS.COM]
For the details of CNO Financial Group, Inc.’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=CNO+Financial+Group%2C+Inc.
These are the top 5 holdings of CNO Financial Group, Inc.iShares Core U.S. Aggregate Bond (AGG) – 1,103,454 shares, 31.92% of the total portfolio. Shares added by 6.16%iShares Core S&P 500 (IVV) – 394,837 shares, 25.38% of the total portfolio. Shares added by 4.50%iShares iBoxx $ Investment Grade Corporate Bond (LQD) – 529,049 shares, 16.84% of the total portfolio. iShares U.S. Preferred Stock ETF (PFF) – 918,000 shares, 9.5% of the total portfolio. New PositionTCP Capital Corp (TCPC) – 2,011,900
- [By WWW.KIPLINGER.COM]
If youre not familiar, the VOO is one of three S&P 500-tracking ETFs the other two are the SPDR S&P 500 ETF Trust (SPY) and the iShares Core S&P 500 ETF (IVV). Each operates slightly differently, but at the end of the day, each provides very honest, tight tracking of the S&P 500. The VOO is simply the cheapest at just 0.05% in expenses, which accounts for most of the slight performance edge over its ETF brethren.
- [By Todd Shriber, ETF Professor]
Passive ETFs continuing to top active rivals is not all about the performance of U.S. stocks this year. Yes, the S&P 500 is up 5.5 percent year-to-date, but that is not a jaw-dropping performance. Much of the ongoing out-performance of passive ETFs over active counterparts this year is attributable to fees. Just look at the rock-bottom fees on ETFs such as the SPDR S&P 500 ETF (NYSE: SPY) and the iShares S&P 500 Core ETF (NYSE: IVV).
investment software: OncoMed Pharmaceuticals, Inc.(OMED)
- [By Teresa Rivas]
OncoMed Pharmaceuticals (OMED) has lost more than a third of its value Monday, after Bayer decided not to exercise its option to license the firms Phase II-ready WNT pathway inhibitors Vantictumab and Ipafricept, which treat pancreatic cancer.
That wasnt the only bad news, however, as the firms randomized-controlled Phase II “YOSEMITE” trial of pancreatic cancer drug demcizumab also missed its primary endpoint.
Leerinks Michael Schmidt and his team reiterated a Market Perform rating on the stock Monday, and lowered their price target from $10 to $6 on the news, calling it a “double setback” for OncoMed.
More detail from the note:
This is a major setback for OMED and in our view for the cancer stem cell targets more broadly, which have been a difficult area of drug development. We’ve been cautious on the probability-of-success of these agents and see more promise on OMED’s recent efforts in building a second area of focus in immuno-oncology. Going forward, OMED plans to review and prioritize its R&D pipeline after results from the still pending tarextumab Phase II “PINNACLE” trial in small cell lung cancer (SCLC) and data from the demcizumab “DENALI” trial in NSCLC are available in 2Q17. We remain MP rated in light of the uncertainties around OMED’s pipeline and strategy at this point. We previously assigned a 30% probability of success (POS) to demcizumab which we now have removed from our model. We also think chances that CELG will opt-into this program are slim and we have removed associated POS-adjusted milestone payments from our model. OMED has cash to run operations through 3Q18.
OncoMed is down 36.1% to $5.60 this afternoon.
- [By Paul Ausick]
OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped nearly 44% Monday to post a new 52-week low of $4.94 after closing Friday at $8.76. The stock’s 52-week high is $15.49. Volume of about 3.3 million shares was nearly 20 times the daily average of around 182,000. A proposed deal with Bayer AG fell through and one of the company’s drugs failed a phase 2 clinical trial.
- [By Paul Ausick]
OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped about 5.3% Wednesday to post a new 52-week low of $4.69 after closing at $4.95 on Tuesday. The stock’s 52-week high is $15.49. Volume was more than double the daily average of around 270,000 shares. The company had no specific news Wednesday.